Core Laboratories (NYSE:CLB) Issues Q4 2026 Earnings Guidance

Core Laboratories (NYSE:CLB) updated its fourth quarter 2026 earnings guidance on Friday. The company provided EPS guidance of 0.120-0.200 for the period, compared to the consensus EPS estimate of 0.190. The company issued revenue guidance of $128.5 million-$134.5 million, compared to the consensus revenue estimate of $134.2 million.

Core Laboratories Stock Down 1.0%

Core Laboratories stock opened at $10.38 on Friday. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 0.41. Core Laboratories has a 1-year low of $9.13 and a 1-year high of $20.36. The company has a fifty day simple moving average of $11.03 and a 200 day simple moving average of $13.96. The company has a market cap of $476.33 million, a P/E ratio of 27.32, a price-to-earnings-growth ratio of 2.09 and a beta of 1.14.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings data on Wednesday, October 28th. The oil and gas company reported $0.16 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.16. The company had revenue of $132.08 million for the quarter, compared to analysts’ expectations of $131.87 million. Core Laboratories had a return on equity of 9.01% and a net margin of 3.42%. The business’s revenue was down 1.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.22 EPS. Research analysts anticipate that Core Laboratories will post 0.56 earnings per share for the current fiscal year.

Core Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Monday, November 9th will be paid a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, November 9th. Core Laboratories’s dividend payout ratio (DPR) is 7.14%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CLB shares. Wall Street Zen raised Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings raised shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday. Finally, Johnson Rice raised Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Thursday, August 13th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Core Laboratories has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Core Laboratories Company Profile

Core Laboratories N.V. (NYSE: CLB) is a global provider of proprietary reservoir description and production enhancement services and products for the energy industry. The company helps oil and natural gas producers evaluate reservoirs, improve well performance, and optimize the recovery of hydrocarbons.

Its reservoir description activities include geological and geochemical analysis, petrophysical services, core and fluid analysis, and laboratory testing used to characterize subsurface formations.